A
11.93
2.67 (28.83%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Aardvark Therapeutics, Inc. | 看涨 | - |
AIStockmoo 评分
0.9
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.88 |
|
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 14.22% |
| 机构持股比例 | 49.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 3,917,299 |
| Silverarc Capital Management, Llc | 30 Sep 2025 | 306,912 |
| Cresset Asset Management, Llc | 30 Sep 2025 | 146,783 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (HC Wainwright & Co., 235.29%) | 购买 |
| 中 | 26.00 (117.94%) | |
| 低 | 18.00 (RBC Capital, 50.88%) | 购买 |
| 平均值 | 28.20 (136.38%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 11.98 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 14 Nov 2025 | 18.00 (50.88%) | 购买 | 9.92 |
| BTIG | 07 Nov 2025 | 26.00 (117.94%) | 购买 | 10.14 |
| Jones Trading | 01 Oct 2025 | 33.00 (176.61%) | 购买 | 14.71 |
| Stifel | 29 Sep 2025 | 24.00 (101.17%) | 购买 | 13.68 |
| HC Wainwright & Co. | 23 Sep 2025 | 40.00 (235.29%) | 购买 | 11.44 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合